Dataset from An Open-Label, Dose-Escalation, Phase 1 Study of the Oral Form of IXAZOMIB (MLN9708), a Second-Generation Proteasome Inhibitor, in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
收藏NIAID Data Ecosystem2026-05-02 收录
下载链接：
https://doi.org/10.25934/00002512
下载链接
链接失效反馈官方服务：
资源简介：
This study will determine the safety profile, tolerability, and maximum tolerated dose (MTD) and disease response of IXAZOMIB administered orally in patients with relapsed and/or refractory multiple myeloma.
创建时间：
2024-11-26
